FY2025 EPS Estimates for ESPR Lifted by Cantor Fitzgerald
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of $0.12 per share for the year, up from their previous […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of $0.12 per share for the year, up from their previous […]
